Application effect of Irbesartan Hydrochlorothiazide,Nifedipine and Rosuvastatin in the prevention of elderly patients with hypertension and hyperlipidemia after cardiac intervention
Objective To explore the application effect of Irbesartan Hydrochlorothiazide,Nifedipine and Rosuvastatin in the prevention of elderly patients with hypertension and hyperlipidemia after percutaneous coronary intervention(PCI).Methods A total of 178 elderly patients with hypertension and hyperlipidemia after PCI who were admitted to Bayannur Hospital from January to December 2019 were selected as the research objects.They were divided into the observation group(92 cases)and the control group(86 cases)by tossing a coin.The observation group was treated with Irbesartan Hydrochloroth-iazide,Nifedipine and Rosuvastatin,and the control group was treated with Nifedipine and Rosuvastatin.Blood pressure(BP),low density lipoprotein cholesterol(LDL-C),high density lipoprotein cholesterol(HDL-C),triglyceride(TG),total cholesterol(TC),small dense low density lipoprotein cholesterol(sd LDL-C),lipoprotein a(Lp[a]),high-sensitivity C-reac-tive protein(hs-CRP),plasma D-dimer(D-D)expression levels were compared between the two groups on the day of dis-charge and 6,12,18,24 months after operation,and adverse cardiovascular events were recorded.Results The expression level of hs-CRP in the observation group was lower than that in the control group 18 months after operation,and the differ-ence was statistically significant(P＜0.05).The BP,sd LDL-C,Lp(a),hs-CRP and D-D of the observation group were lower than those of the control group 24 months after operation,and the differences were statistically significant(P＜0.05).The in-cidence of adverse cardiovascular events in the observation group was lower than that in the control group,with statistically significant difference(P＜0.05).Conclusion The prophylactic administration of Irbesartan Hydrochlorothiazide,Nifedipine and Rosuvastatin after PCI can effectively reduce the blood pressure and blood lipid levels in elderly patients with severe arteriosclerosis caused by hypertension and hyperlipidemia,and reduce the incidence of adverse cardiovascular events.
维普
万方数据
